| NCT01943526 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2011-11-30 | |
| NCT03046251 | State University of New York at Buffalo | Multiple Sclerosis | 2015-08 | PHASE4 |
| NCT00030966 | Biogen|Elan Pharmaceuticals | Multiple Sclerosis, Relapsing-Remitting | 2002-01 | PHASE3 |
| NCT01485003 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2012-02-07 | |
| NCT01077466 | Rigshospitalet, Denmark|Copenhagen University Hospital, Hvidovre|Biogen|University of Copenhagen|Signifikans ApS | Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis | 2010-03 | PHASE2 |
| NCT02176031 | Dana-Farber Cancer Institute|Biogen | Graft Versus Host Disease | 2015-01 | PHASE2 |
| NCT01071083 | Biogen|Elan Pharmaceuticals | Relapsing Remitting Multiple Sclerosis | 2010-03 | PHASE2 |
| NCT00675428 | Biogen | Multiple Myeloma | 2008-09 | PHASE1|PHASE2 |
| NCT03516526 | Amsterdam UMC, location VUmc|Prothya Biosolutions|Erasmus Medical Center|St. Antonius Hospital|OLVG|Rijnstate Hospital | Multiple Sclerosis | 2016-11-03 | PHASE4 |
| NCT02386566 | Biogen | Multiple Sclerosis | 2015-03-20 | |
| NCT00097760 | Biogen|Elan Pharmaceuticals | Multiple Sclerosis, Relapsing-Remitting | 2003-06 | PHASE2 |
| NCT02133924 | John Levine|Biogen | Acute Graft Versus Host Disease | 2016-08 | PHASE2 |
| NCT02159573 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2014-07 | |
| NCT06705608 | University of British Columbia | Multiple Sclerosis|Skin Cancer|Skin Cancer Melanoma|Skin Cancers - Basal Cell Carcinoma|Skin Cancer, Squamous Cell|Multiple Sclerosis (MS) - Relapsing-remitting | 2003-01-01 | |
| NCT03283371 | Biogen | Epilepsy, Focal Seizures, Partial Seizures | 2018-03-20 | PHASE2 |
| NCT00871780 | Biogen|Elan Pharmaceuticals | Relapsing Remitting Multiple Sclerosis (RRMS) | 2009-08 | PHASE4 |
| NCT03093064 | King´s College London|South London and Maudsley NHS Foundation Trust | Schizophrenia | 2017-04-01 | PHASE1 |
| NCT00559702 | Biogen|Elan Pharmaceuticals | Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis | 2007-10 | PHASE1 |
| NCT00424788 | Biogen | Relapsing Forms of Multiple Sclerosis | 2007-01 | EARLY_PHASE1 |
| NCT01440101 | Biogen | Multiple Sclerosis | 2010-11 | PHASE2|PHASE3 |
| NCT02483845 | Phoenix Neurological Associates, LTD | Inclusion Body Myositis (IBM) | 2013-05 | PHASE1 |
| NCT05627271 | Novartis Pharmaceuticals | Multiple Sclerosis | 2023-01-10 | |
| NCT00306592 | Biogen|Elan Pharmaceuticals | Multiple Sclerosis, Relapsing-Remitting | 2006-03 | PHASE3 |
| NCT04777539 | Nantes University Hospital|Rennes University Hospital | Multiple Sclerosis (MS) | 2021-06-14 | |
| NCT02775110 | University at Buffalo | Multiple Sclerosis | 2012-11 | PHASE4 |
| NCT02137109 | Biogen | Multiple Sclerosis | 2014-03 | |
| NCT05177718 | Vanderbilt University Medical Center|Biogen | Multiple Sclerosis | 2022-09-16 | PHASE4 |
| NCT00055367 | Biogen|Elan Pharmaceuticals | Crohn´s Disease | 2002-04 | PHASE2 |
| NCT01884935 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2013-07 | PHASE1 |
| NCT00032799 | Biogen|Elan Pharmaceuticals | Crohn´s Disease | 2001-12 | PHASE3 |
| NCT05532163 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 2023-01-23 | PHASE4 |
| NCT05236777 | Biogen|ReMuS Registry | Multiple Sclerosis | 2019-01-01 | |
| NCT03689972 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 2018-11-27 | PHASE3 |
| NCT00078611 | Biogen|Elan Pharmaceuticals | Crohn´s Disease | 2004-03 | PHASE3 |
| NCT01405820 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2011-08 | PHASE2 |
| NCT01416181 | Biogen | Secondary Progressive Multiple Sclerosis | 2011-09-13 | PHASE3 |
| NCT05688436 | Biogen | Multiple Sclerosis | 2021-09-24 | |
| NCT03811886 | Case Comprehensive Cancer Center | Pulmonary Metastatic Osteosarcoma (pOS) | 2024-12-01 | PHASE1|PHASE2 |
| NCT04964700 | Multiple Sclerosis Center of Northeastern New York | Multiple Sclerosis | 2021-05-06 | |
| NCT05618301 | Washington University School of Medicine|BioLineRx, Ltd.|Biogen|Ayrmid Pharma | Sickle Cell Disease | 2023-07-07 | PHASE1 |
| NCT00280956 | Biogen|Elan Pharmaceuticals | Crohn´s Disease | 2002-07 | PHASE4 |
| NCT01144052 | Claudio Gobbi|Ospedale Civico, Lugano | Relapsing-remitting Multiple Sclerosis | 2010-06 | PHASE4 |
| NCT00818038 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2009-03 | |
| NCT05762003 | IMPULS Endowment Fund | Multiple Sclerosis | 2019-01-01 | |
| NCT00083759 | Biogen|Elan Pharmaceuticals | Rheumatoid Arthritis | 2004-05 | PHASE2 |
| NCT01070823 | Biogen|United BioSource, LLC|Elan Pharmaceuticals | Multiple Sclerosis | 2010-03 | |
| NCT02325440 | University Hospital Muenster|Novartis | Relapsing Remitting Multiple Sclerosis | 2014-03 | PHASE4 |
| NCT00536120 | Biogen | Multiple Sclerosis | 2008-01 | PHASE4 |
| NCT05701423 | Biogen | Multiple Sclerosis | 2023-02-08 | |
| NCT01416155 | Biogen | Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis | 2010-10 | PHASE2 |
| NCT00884481 | Biogen | Relapsing-Remitting Multiple Sclerosis|Fatigue | 2009-03-23 | |
| NCT00801125 | Biogen|Elan Pharmaceuticals | Crohn´s Disease | 2008-12 | PHASE4 |
| NCT01455220 | University of South Florida | Multiple Sclerosis | 2011-01 | NA |
| NCT00831649 | Biogen|Elan Pharmaceuticals | Rheumatoid Arthritis | 2004-09 | PHASE2 |
| NCT00027300 | Biogen|Elan Pharmaceuticals | Multiple Sclerosis, Relapsing-Remitting | 2001-11 | PHASE3 |
| NCT01058005 | Biogen|Elan Pharmaceuticals | Relapsing Remitting Multiple Sclerosis | 2010-03 | PHASE3 |
| NCT01591551 | Cornerstone Health Care, PA|Biogen | Multiple Sclerosis, Relapsing-Remitting | 2012-03 | PHASE4 |
| NCT01070836 | Biogen | Relapsing Multiple Sclerosis | 2010-03 | |
| NCT00055536 | Biogen|Elan Pharmaceuticals | Crohn´s Disease | 2002-04 | PHASE2 |
| NCT05304520 | Biogen | Relapsing-Remitting Multiple Sclerosis (RRMS) | 2021-10-12 | |
| NCT00032786 | Biogen|Elan Pharmaceuticals | Crohn´s Disease | 2002-03 | PHASE3 |
| NCT00744679 | Biogen|Elan Pharmaceuticals | Multiple Sclerosis | 2008-11 | PHASE4 |
| NCT02142192 | Biogen | Relapsing Multiple Sclerosis | 2014-12-01 | PHASE2 |
| NCT04225312 | Amsterdam UMC, location VUmc|Stichting MS Research|Innovatiefonds Zorgverzekeraars|Stichting Treatmeds | Relapsing Remitting Multiple Sclerosis | 2020-02-03 | PHASE4 |
| NCT02677077 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2015-12-31 | |
| NCT05925049 | Biogen | Multiple Sclerosis | 2023-06-30 | |
| NCT01955707 | Biogen | Acute Ischemic Stroke | 2014-01 | PHASE2 |
| NCT02241785 | Biogen | Relapsing Multiple Sclerosis | 2014-09-30 | PHASE4 |
| NCT02342704 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2014-11-30 | PHASE4 |
| NCT02769689 | University Hospital, Clermont-Ferrand | Multiple Sclerosis | 2019-06-12 | PHASE4 |
| NCT02730455 | Biogen | Acute Ischemic Stroke | 2016-07-18 | PHASE2 |
| NCT00297232 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2006-03 | PHASE3 |
| NCT04832399 | Biogen | Relapsing Remitting Multiple Sclerosis | 2013-11-12 | |
| NCT00707512 | Biogen | Crohn´s Disease | 2008-06-30 | |
| NCT04048577 | Berkovich, Regina MD, PhD Inc.|Biogen|Cedars-Sinai Medical Center | Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting | 2019-07-03 | PHASE4 |
| NCT00942214 | University Hospital, Toulouse | Multiple Sclerosis | 2009-06 | PHASE4 |
| NCT01065727 | Rennes University Hospital | Multiple Sclerosis | 2010-02 | NA |
| NCT02142205 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2012-05 | PHASE4 |